Cotinga Pharmaceuticalsの企業価値
Cotinga Pharmaceuticalsの企業価値は何ですか。
Cotinga Pharmaceuticals, Inc.の企業価値は1.07M$です。
企業価値の定義は何ですか。
企業価値は、企業の総市場価値の尺度です。これは、負債、少数株主持分および優先株式から現金および現金同等物を差し引いた時価総額として計算されます。
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
TSXVのセクタHealth Careにおける企業価値の企業と比べるCotinga Pharmaceuticals
Cotinga Pharmaceuticalsは何をしますか。
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Cotinga Pharmaceuticalsと類似の企業価値
- Core Canadian Dividend Trustの企業価値は1.04M$です。
- Q Technologyの企業価値は1.05M$です。
- Predictiv AIの企業価値は1.06M$です。
- Orestone Miningの企業価値は1.06M$です。
- RNY Property Trustの企業価値は1.06M$です。
- Zinc One Resourcesの企業価値は1.06M$です。
- Cotinga Pharmaceuticalsの企業価値は1.07M$です。
- Thredの企業価値は1.07M$です。
- BPM Mineralsの企業価値は1.07M$です。
- Roots Sustainable Agricultural Technologiesの企業価値は1.07M$です。
- Immobiliere Distri-Land NVの企業価値は1.07M$です。
- Pangolin Diamondsの企業価値は1.08M$です。
- Vintana Plcの企業価値は1.09M$です。